TransMedics Group stock gets USD 120.00 target from Barclays

Published on 10/08/2026 at 06:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TransMedics Group stock entered Barclays coverage on October 7 with an Overweight rating. Q2 revenue rose 20.7 percent to USD 189.95 million.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group (ISIN US89377M1099) was last at USD 81.07 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, with a quoted change of 0.98 percent from USD 80.28. Barclays began coverage with an Overweight rating and a USD 120.00 price target, giving the medical-device company a fresh analyst benchmark, according to MarketBeat on October 7, 2026.

Barclays sets a USD 120 target

The Barclays target lies 48.0 percent above the October 7 price. That gap reflects the difference between a new single-house view and the stock's current market value, rather than a company forecast.

The wider analyst picture is less uniform. MarketBeat reported a Hold consensus from 13 analysts, with an average 12-month price target of USD 121.00. That consensus target lies 49.3 percent above the October 7 price, while the published analyst range in the same coverage spans from a Sell view to an Overweight rating.

Q2 revenue beats the estimate

TransMedics reported USD 189.95 million in Q2 2026 revenue, up 20.7 percent from the year-ago quarter and above the USD 184.00 million consensus estimate, according to MarketBeat. The comparison is constructive on sales, but adjusted EPS of USD 0.44 missed the USD 0.50 consensus estimate by USD 0.06.

The earnings mix gives the analyst target an important counterweight. Q2 adjusted EPS was below consensus even as revenue exceeded expectations, so future valuation support depends on converting the Organ Care System platform's sales growth into more consistent earnings.

Stock remains below its yearly high

TransMedics Group's October 7 trading range ran from USD 80.96 to USD 83.90, with volume of 962,415 shares. The 52-week range was USD 60.10 to USD 156.00, placing the last price USD 74.93 below the yearly high and USD 20.97 above the yearly low.

The company develops Organ Care System technology for heart, lung and liver transplantation. Its USD 2.8 billion market capitalization gives the Barclays target and the analyst consensus a direct valuation test against a business that delivered double-digit quarterly revenue growth but a quarterly adjusted EPS miss.